HCPCS Level II › Q codes › Q0220

Q0220

Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), 300 mg

TerminatedHCPCS Level II code.

Still listed by CMS but carries a termination date, so it is not valid for a current date of service.

Terminated with effect from 2024-12-12. First published 2023. CMS still lists this code in the current quarterly file - it carries a termination date rather than being removed.

What has happened to this code

Every change the publisher made, from 2025 to now.

  1. April 2025 Terminated by CMS